Arbutus Biopharma Corp’s filing revealed that its Director McElhaugh Michael J. acquired Company’s shares for reported $0.8 million on Apr 21 ’25. In the deal valued at $3.26 per share,246,886 shares were bought.
Then, McElhaugh Michael J. bought 53,114 shares, generating $170,098 in total proceeds.
Before that, Sofia Michael J. bought 250,000 shares. Arbutus Biopharma Corp shares valued at $875,000 were divested by the Officer at a price of $3.50 per share.
Jefferies upgraded its Arbutus Biopharma Corp [ABUS] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late February with a ‘”a Hold”‘ rating. H.C. Wainwright began covering ABUS with “Buy” recommendation on December 17, 2020.
Price Performance Review of ABUS
On Monday, Arbutus Biopharma Corp [NASDAQ:ABUS] saw its stock fall -2.23% to $3.51. Over the last five days, the stock has gained 5.09%. Arbutus Biopharma Corp shares have risen nearly 7.34% since the year began. Nevertheless, the stocks have risen 30.48% over the past one year. While a 52-week high of $4.72 was reached on 05/02/25, a 52-week low of $2.70 was recorded on 04/09/25. SMA at 50 days reached $3.31, while 200 days put it at $3.59.
Levels Of Support And Resistance For ABUS Stock
The 24-hour chart illustrates a support level at 3.36, which if violated will result in even more drops to 3.21. On the upside, there is a resistance level at 3.66. A further resistance level may holdings at 3.81. The Relative Strength Index (RSI) on the 14-day chart is 58.12, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 29.45%. Stochastics %K at 83.48% indicates the stock is a selling.
